RxDoctor Payments Data

Hannah-Beth Chapman, APRN

Psychiatric/Mental Health · Tulsa, OKNPI 1639934714

Payments from drug & device makers

$2,472in general payments, 2019–2025

Across 144 payments — averaging $17.17 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Teva Pharmaceuticals USA, Inc.$958
  • AbbVie$504
  • Johnson & Johnson$398
  • Vanda Pharmaceuticals Inc.$259
  • Otsuka America Pharmaceutical, Inc.$172
  • Alkermes, Inc.$145
  • plus $36 from 2 others

What the payments were for

  • Food & beverage$2,26191%
  • Education$2119%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,472 in reported general payments places this provider in the 70th percentile of 231 psychiatric/mental health providers in Oklahoma.

See all psychiatric/mental health providers in Oklahoma

Medicare billing

Part B allowed, 2024
$32,978
Medicare patients
91
Services billed
407

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VraylarCariprazine Hcl31$49,919
UzedyRisperidone15$40,779
Olanzapine42$987
Risperidone42$924
Hydroxyzine Hcl34$911
Quetiapine Fumarate51$709
Venlafaxine Hcl36$592
Aripiprazole12$553
Duloxetine Hcl28$508
Lamotrigine35$458
Buspirone Hcl26$417
Mirtazapine19$391
Lurasidone Hcl16$371
Clonazepam25$301
Bupropion XlBupropion Hcl21$264

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieVraylar$504$49,91931 claims
Teva Pharmaceuticals USA, Inc.Uzedy$958$40,77915 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 231 psychiatric/mental health providers in Oklahoma.

Other psychiatric/mental health in Tulsa

See the full list for Oklahoma

Where these figures come from

Is this you, or does something look wrong? →